Glimepiride extended release/metformin extended release - GlaxoSmithKline

Drug Profile

Glimepiride extended release/metformin extended release - GlaxoSmithKline

Alternative Names: Metformin extended release/glimepiride extended release - GlaxoSmithKline

Latest Information Update: 29 Apr 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antihyperglycaemics; Biguanides; Small molecules; Sulfones; Sulfonylureas
  • Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; Insulinotropin agonists; Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 30 Aug 2013 GlaxoSmithKline terminates phase I trial in Type 2 diabetes mellitus (in volunteers) in Australia (NCT01725672)
  • 01 Sep 2012 Phase-I clinical trials in Type-2 diabetes mellitus (in volunteers) in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top